Millennium Management LLC Buys 657,420 Shares of Zura Bio Limited (NASDAQ:ZURA)

Millennium Management LLC boosted its holdings in Zura Bio Limited (NASDAQ:ZURA - Free Report) by 1,499.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 701,278 shares of the company's stock after purchasing an additional 657,420 shares during the quarter. Millennium Management LLC owned 1.07% of Zura Bio worth $1,753,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. American Century Companies Inc. acquired a new stake in Zura Bio in the 4th quarter worth about $27,000. Prudential Financial Inc. acquired a new stake in Zura Bio in the 4th quarter worth about $28,000. XTX Topco Ltd acquired a new stake in Zura Bio in the 4th quarter worth about $44,000. SG Americas Securities LLC raised its position in shares of Zura Bio by 51.6% in the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock valued at $58,000 after buying an additional 7,828 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Zura Bio by 68.6% in the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after buying an additional 9,379 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ZURA shares. HC Wainwright restated a "buy" rating on shares of Zura Bio in a research report on Thursday, April 3rd. Oppenheimer dropped their target price on shares of Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, May 9th. Chardan Capital dropped their target price on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Finally, Guggenheim restated a "buy" rating and issued a $15.00 target price on shares of Zura Bio in a research report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Zura Bio presently has an average rating of "Buy" and a consensus price target of $14.33.

Zura Bio Stock Performance

Shares of Zura Bio stock traded up $0.11 during midday trading on Friday, hitting $1.26. 995,668 shares of the company traded hands, compared to its average volume of 426,811. The stock has a market cap of $86.15 million, a price-to-earnings ratio of -1.80 and a beta of 0.05. The firm's fifty day moving average price is $1.20 and its 200-day moving average price is $1.68. Zura Bio Limited has a 12 month low of $0.97 and a 12 month high of $5.07.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Equities research analysts forecast that Zura Bio Limited will post -0.65 earnings per share for the current year.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.